Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia cepacia Ribosomal RNA small subunit methyltransferase A (rsmA) CSB-YP451756BXS
CSB-EP451756BXS
CSB-BP451756BXS
CSB-MP451756BXS
CSB-EP451756BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia ATP-dependent Clp protease ATP-binding subunit ClpX (clpX) CSB-YP451757BXS
CSB-EP451757BXS
CSB-BP451757BXS
CSB-MP451757BXS
CSB-EP451757BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia 6,7-dimethyl-8-ribityllumazine synthase (ribH) CSB-YP451758BXS
CSB-EP451758BXS
CSB-BP451758BXS
CSB-MP451758BXS
CSB-EP451758BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (ispD) CSB-YP451759BXS
CSB-EP451759BXS
CSB-BP451759BXS
CSB-MP451759BXS
CSB-EP451759BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Ribonuclease HII (rnhB) CSB-YP451760BXS
CSB-EP451760BXS
CSB-BP451760BXS
CSB-MP451760BXS
CSB-EP451760BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia DNA ligase (ligA), partial CSB-YP451761BXS
CSB-EP451761BXS
CSB-BP451761BXS
CSB-MP451761BXS
CSB-EP451761BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (accA) CSB-YP451762BXS
CSB-EP451762BXS
CSB-BP451762BXS
CSB-MP451762BXS
CSB-EP451762BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Co-chaperone protein hscB homolog (hscB) CSB-YP451763BXS
CSB-EP451763BXS
CSB-BP451763BXS
CSB-MP451763BXS
CSB-EP451763BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Chaperone protein DnaK (dnaK), partial CSB-YP451764BXS
CSB-EP451764BXS
CSB-BP451764BXS
CSB-MP451764BXS
CSB-EP451764BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia UPF0246 protein BceJ2315_22780 (BceJ2315_22780) CSB-YP451765BXS
CSB-EP451765BXS
CSB-BP451765BXS
CSB-MP451765BXS
CSB-EP451765BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Anhydro-N-acetylmuramic acid kinase (anmK) CSB-YP451766BXS
CSB-EP451766BXS
CSB-BP451766BXS
CSB-MP451766BXS
CSB-EP451766BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia N-acetyl-gamma-glutamyl-phosphate reductase (argC) CSB-YP451767BXS
CSB-EP451767BXS
CSB-BP451767BXS
CSB-MP451767BXS
CSB-EP451767BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Cyanate hydratase (cynS) CSB-YP451768BXS
CSB-EP451768BXS
CSB-BP451768BXS
CSB-MP451768BXS
CSB-EP451768BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Ureidoglycolate lyase (BceJ2315_61450) CSB-YP451769BXS
CSB-EP451769BXS
CSB-BP451769BXS
CSB-MP451769BXS
CSB-EP451769BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Probable tRNA threonylcarbamoyladenosine biosynthesis protein Gcp (gcp) CSB-YP451770BXS
CSB-EP451770BXS
CSB-BP451770BXS
CSB-MP451770BXS
CSB-EP451770BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Glucosamine-6-phosphate deaminase (nagB) CSB-YP451771EYZ
CSB-EP451771EYZ
CSB-BP451771EYZ
CSB-MP451771EYZ
CSB-EP451771EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Methionine--tRNA ligase (metG), partial CSB-YP451772EYZ
CSB-EP451772EYZ
CSB-BP451772EYZ
CSB-MP451772EYZ
CSB-EP451772EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UPF0352 protein PMI0824 (PMI0824) CSB-YP451773EYZ
CSB-EP451773EYZ
CSB-BP451773EYZ
CSB-MP451773EYZ
CSB-EP451773EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Protease HtpX (htpX), partial CSB-YP451774EYZ1
CSB-EP451774EYZ1
CSB-BP451774EYZ1
CSB-MP451774EYZ1
CSB-EP451774EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Bifunctional polymyxin resistance protein ArnA (arnA), partial CSB-YP451775EYZ
CSB-EP451775EYZ
CSB-BP451775EYZ
CSB-MP451775EYZ
CSB-EP451775EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>